Jim Simons Biotechnology

Renaissance Technologies LLC

$70.6 Billion
Q3 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade
IBRX Immunity Bio, Inc.	$833M	$2.5 Million 0.0% of portfolio	1,016,199	Q3 2025 New
VCYT Veracyte, Inc.	$2.82B	$2.49 Million 0.0% of portfolio	72,584	Q3 2025 Reduced 88.11%
TARS Tarsus Pharmaceuticals, Inc.	$1.92B	$2.47 Million 0.0% of portfolio	41,600	Q3 2025 New
KROS Keros Therapeutics, Inc.	$445M	$2.45 Million 0.0% of portfolio	154,700	Q3 2025 Added 5.53%
SEER Seer, Inc.	$117M	$2.41 Million 0.0% of portfolio	1,110,300	Q3 2025 Reduced 0.66%
TYRA Tyra Biosciences, Inc.	$652M	$2.38 Million 0.0% of portfolio	170,100	Q3 2025 Added 25.91%
NKTX Nkarta, Inc.	$91M	$2.37 Million 0.0% of portfolio	1,145,077	Q3 2025 Added 64.43%
IMNM Immunome Inc.	$208M	$2.34 Million 0.0% of portfolio	202,300	Q3 2025 Added 103.58%
ACIU Ac Immune Sa	$276M	$2.33 Million 0.0% of portfolio	770,419	Q3 2025 Reduced 6.99%

ANNX Annexon, Inc.	$136M	$2.25 Million 0.0% of portfolio	753,579	Q3 2025 Reduced 3.13%
XNCR Xencor Inc	$891M	$2.23 Million 0.0% of portfolio	190,389	Q3 2025 Added 242.43%
ERAS Erasca, Inc.	$315M	$2.21 Million 0.0% of portfolio	1,015,005	Q3 2025 Added 36.7%
BDTX Black Diamond Therapeutics, Inc.	$153M	$2.21 Million 0.0% of portfolio	599,400	Q3 2025 Added 258.71%
ELYM Eliem Therapeutics, Inc.	$109M	$2.21 Million 0.0% of portfolio	537,100	Q3 2025 Added 8.4%
FULC Fulcrum Therapeutics, Inc.	$451M	$2.16 Million 0.0% of portfolio	248,200	Q3 2025 Added 216.18%
CCCC C4 Therapeutics, Inc.	$121M	$2.08 Million 0.0% of portfolio	936,950	Q3 2025 Reduced 14.29%
DSGN Design Therapeutics, Inc.	$411M	$2.07 Million 0.0% of portfolio	274,300	Q3 2025 Added 2.43%
CGEN Compugen LTD	$146M	$2.02 Million 0.0% of portfolio	1,405,335	Q3 2025 Added 5.9%

CRBU Caribou Biosciences, Inc.	$124M	$1.82 Million 0.0% of portfolio	780,421	Q3 2025 Added 46.66%
NRIX Nurix Therapeutics, Inc.	$603M	$1.71 Million 0.0% of portfolio	184,800	Q3 2025 Added 743.84%
FATE Fate Therapeutics Inc	$93.1M	$1.59 Million 0.0% of portfolio	1,262,515	Q3 2025 Added 488.69%
PLRX Pliant Therapeutics, Inc.	$84.2M	$1.5 Million 0.0% of portfolio	1,011,802	Q3 2025 Added 406.03%
ACET Adicet Bio, Inc.	$26.4M	$1.48 Million 0.0% of portfolio	1,828,949	Q3 2025 Added 58.51%
TCRX T Scan Therapeutics, Inc.	$21.6M	$1.47 Million 0.0% of portfolio	829,919	Q3 2025 Added 4.78%
OMER Omeros Corp	$465M	$1.41 Million 0.0% of portfolio	344,500	Q3 2025 Reduced 9.98%
TARA Protara Therapeutics, Inc.	$62.1M	$1.37 Million 0.0% of portfolio	314,300	Q3 2025 Added 110.66%
ATOS Atossa Therapeutics, Inc.	$103M	$1.33 Million 0.0% of portfolio	1,548,663	Q3 2025 Reduced 14.54%
IPSC Century Therapeutics, Inc.	$27.7M	$1.29 Million 0.0% of portfolio	2,586,900	Q3 2025 Added 27.91%
RPTX Repare Therapeutics Inc.	$69.2M	$1.27 Million 0.0% of portfolio	724,160	Q3 2025 Added 38.5%
PYXS Pyxis Oncology, Inc.	$158M	$1.26 Million 0.0% of portfolio	576,336	Q3 2025 Added 37.94%
STRO Sutro Biopharma, Inc.	$49.6M	$1.25 Million 0.0% of portfolio	1,424,797	Q3 2025 Added 56.02%
VYGR Voyager Therapeutics, Inc.	$155M	$1.21 Million 0.0% of portfolio	262,450	Q3 2025 Reduced 33.07%
BMEA Biomea Fusion, Inc.	$37.5M	$1.2 Million 0.0% of portfolio	595,900	Q3 2025 New
MREO Mereo Biopharma Group PLC	$227M	$1.18 Million 0.0% of portfolio	590,871	Q3 2025 Reduced 60.09%
XOMA Xoma Corp	$371M	$1.07 Million 0.0% of portfolio	28,900	Q3 2025 Added 142.86%
CSBR Champions Oncology, Inc.	$91.8M	$1.07 Million 0.0% of portfolio	167,261	Q3 2025 Reduced 7.61%
ABOS Acumen Pharmaceuticals, Inc.	$72.1M	$1.04 Million 0.0% of portfolio	584,292	Q3 2025 Added 136.95%
ALDX Aldeyra Therapeutics, Inc.	$296M	$1.02 Million 0.0% of portfolio	197,300	Q3 2025 Added 74.91%
CGTX Cognition Therapeutics Inc	$35.2M	$956,000 0.0% of portfolio	713,500	Q3 2025 Added 640.15%
ICCC Immucell Corp	$42.6M	$943,000 0.0% of portfolio	157,289	Q3 2025 Reduced 1.69%
HOWL Werewolf Therapeutics, Inc.	$27.8M	$921,000 0.0% of portfolio	456,000	Q3 2025 Added 44.17%
SVRA Savara Inc	$495M	$915,000 0.0% of portfolio	260,100	Q3 2025 New
ELDN Eledon Pharmaceuticals, Inc.	$24.2M	$900,000 0.0% of portfolio	349,200	Q3 2025 Added 83.14%
EQ Equillium, Inc.	$35M	$879,000 0.0% of portfolio	614,923	Q3 2025 Added 124.34%
OLMA Olema Pharmaceuticals, Inc.	$351M	$869,000 0.0% of portfolio	90,100	Q3 2025 Added 53.23%
DNLI Denali Therapeutics Inc.	$2.34B	$868,000 0.0% of portfolio	59,800	Q3 2025 Reduced 69.44%
NAUT Nautilus Biotechnology, Inc.	$227M	$846,000 0.0% of portfolio	1,007,662	Q3 2025 Added 62.55%
AADI Aadi Bioscience, Inc.	$35.9M	$782,000 0.0% of portfolio	457,422	Q3 2025 Reduced 0.17%
CDXS Codexis, Inc.	$108M	$757,000 0.0% of portfolio	310,486	Q3 2025 Reduced 58.9%
VTYX Ventyx Biosciences, Inc.	$523M	$730,000 0.0% of portfolio	235,000	Q3 2025 Added 229.59%

Shares Options

Jim Simons

Jim Simons is the founder and chairman of Renaissance Technologies, a successful investment firm that uses quantitative approaches to investing. Simons is known for his expertise in mathematical modeling and has a reputation for being a skilled and successful investor. He has generated strong returns for his clients over the long term.

Track Jim Simons's portfolio

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account